Cheap Broker Fees
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Adaptive Biotechnologies Corporation is a biotechnology business based in the US. Adaptive Biotechnologies Corporation shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptive Biotechnologies Corporation employs 622 staff and has a trailing 12-month revenue of around USD$133.4 million.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Adaptive Biotechnologies Corporation's stock price has had significant negative movement.
Its last market close was $33.5, which is 1.93% down on its pre-crash value of $34.16 and 120.54% up on the lowest point reached during the March crash when the stocks fell as low as $15.19.
If you had bought $1,000 worth of Adaptive Biotechnologies Corporation stocks at the start of February 2020, those stocks would have been worth $755.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,116.56.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$33.50|
|52-week range||$29.74 - $71.25|
|50-day moving average||$35.82|
|200-day moving average||$37.19|
|Wall St. target price||$56.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.24|
|1 week (2021-10-07)||N/A|
|1 month (2021-09-17)||-15.72%|
|3 months (2021-07-17)||-11.59%|
|6 months (2021-04-16)||-20.30%|
|1 year (2020-10-16)||-35.19%|
|2 years (2019-10-18)||14.45%|
|3 years (2018-10-14)||N/A|
|5 years (2016-10-14)||N/A|
|Revenue TTM||$133.4 million|
|Gross profit TTM||$-40,220,000|
|Return on assets TTM||-11.41%|
|Return on equity TTM||-28%|
|Market capitalisation||$4.7 billion|
TTM: trailing 12 months
There are currently 4.4 million Adaptive Biotechnologies Corporation shares held short by investors – that's known as Adaptive Biotechnologies Corporation's "short interest". This figure is 4.7% up from 4.2 million last month.
There are a few different ways that this level of interest in shorting Adaptive Biotechnologies Corporation shares can be evaluated.
Adaptive Biotechnologies Corporation's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies Corporation shares currently shorted divided by the average quantity of Adaptive Biotechnologies Corporation shares traded daily (recently around 588421.7623498). Adaptive Biotechnologies Corporation's SIR currently stands at 7.49. In other words for every 100,000 Adaptive Biotechnologies Corporation shares traded daily on the market, roughly 7490 shares are currently held short.
However Adaptive Biotechnologies Corporation's short interest can also be evaluated against the total number of Adaptive Biotechnologies Corporation shares, or, against the total number of tradable Adaptive Biotechnologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies Corporation shares in existence, roughly 30 shares are currently held short) or 0.0473% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies Corporation shares, roughly 47 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies Corporation.
We're not expecting Adaptive Biotechnologies Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Adaptive Biotechnologies Corporation's shares have ranged in value from as little as $29.735 up to $71.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies Corporation's is 0.3018. This would suggest that Adaptive Biotechnologies Corporation's shares are less volatile than average (for this exchange).
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
This guide will show you step-by-step instructions on how to buy the Quickswap (QUICK) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the DexTools (DEXT) token as well as a list of exchanges you can trade it on.
DeFi tokens compose a prominent sector in the cryptocurrency markets. Learn the basics of these tokens here.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.